Bipolar Disorder Treatment Market, By Drug Class (Antipsychotics, Antidepressants, Mood Stabilizers, and Anti-anxiety Drugs and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Bipolar disorder is a lifelong disease, which can be managed with proper medication. The medications used to manage bipolar disorder symptoms include mood stabilizers and atypical antipsychotics. Mood stabilizers such as lithium and other drugs are used for the treatment of bipolar disorders by suppressing mood swings such as mania and depression. Cariprazine is an atypical antipsychotic drug indicated for the treatment of depressive episodes associated with bipolar I disorder in adults. Antidepressant medications are also prescribed to treat depressive episodes in bipolar disorder. Antidepressants combined with mood stabilizers are indicated to prevent triggering of maniac episode in patients with bipolar disorder.
Market Dynamics
The increasing adoption of inorganic growth strategies such as mergers, agreements, and collaborations by key players operating in the market are expected to propel the market growth over the forecast period. For instance, in July 2021, Gedeon Richter plc, entered into an exclusive license agreement with Hikma Pharmaceuticals Plc. to commercialize cariprazine, a novel antipsychotic drug, in certain Middle East and North African or MENA markets. Moreover, earlier in August 2016, Gedeon RichterPlc. and Recordati signed an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic drug in Western Europe, Algeria, and Tunisia.
Key features of the study:
This report provides in-depth analysis of the global bipolar disorder treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bipolar disorder treatment market based on the following parameters – company overview, financial performance, Device portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future device launches, drug class up-gradation, market expansion, and marketing tactics
The global bipolar disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder treatment market
Detailed Segmentation:
Global Bipolar Disorder Treatment Market, By Drug Class:
Antipsychotics
Antidepressants
Mood Stabilizers
Anti-anxiety Drugs and Others
Global Bipolar Disorder Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Bipolar Disorder Treatment Market, By Region:
North America
By Drug Class:
Antipsychotics
Antidepressants
Mood Stabilizers
Anti-anxiety Drugs and Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Class:
Antipsychotics
Antidepressants
Mood Stabilizers
Anti-anxiety Drugs and Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Antipsychotics
Antidepressants
Mood Stabilizers
Anti-anxiety Drugs and Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Antipsychotics
Antidepressants
Mood Stabilizers
Anti-anxiety Drugs and Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
Antipsychotics
Antidepressants
Mood Stabilizers
Anti-anxiety Drugs and Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Antipsychotics
Antidepressants
Mood Stabilizers
Anti-anxiety Drugs and Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Takeda Pharmaceutical Company Limited*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Pfizer, Inc.
Allergan plc
Otsuka Holdings Co. Ltd.
Johnson & Johnson
Eli Lilly and Company
GlaxoSmithKline plc
AstraZeneca Plc
Novartis International AG
AbbVie Inc.
H. Lundbeck A/S
Minerva Neurosciences
Sumitomo Dainippon Pharma Co., Ltd.
Intra-Cellular Therapies Inc.
Gedeon Richter Plc.
Indivior PLC
“*” marked represents similar segmentation in other categories in the respective section.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook